Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3037% below fair value
$18.41+0.00 (0.00%)
Close on Nov 20, 2026Market cap $1.33BP/E 9.3Yield –
Innoviva free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Innoviva's free cash flow for the twelve months ending Sep 30, 2026 was $182.51M, down 9.0% year over year. For fiscal 2025 it was $195.80M, up 3.9% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $363.81M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.80M | +3.9% |
| FY2024 | Dec 31, 2024 | $188.42M | +34.0% |
| FY2023 | Dec 31, 2023 | $140.65M | -30.3% |
| FY2022 | Dec 31, 2022 | $201.66M | -44.6% |
| FY2021 | Dec 31, 2021 | $363.81M | +16.2% |
| FY2020 | Dec 31, 2020 | $313.10M | +21.6% |
| FY2019 | Dec 31, 2019 | $257.45M | +15.2% |
| FY2018 | Dec 31, 2018 | $223.53M | +57.7% |
| FY2017 | Dec 31, 2017 | $141.75M | +133.5% |
| FY2016 | Dec 31, 2016 | $60.71M | +499.6% |
| FY2015 | Dec 31, 2015 | $10.12M | – |
| FY2014 | Dec 31, 2014 | -$131.41M | – |
| FY2013 | Dec 31, 2013 | -$132.34M | – |
| FY2012 | Dec 31, 2012 | -$130.10M | – |
| FY2011 | Dec 31, 2011 | -$91.97M | – |
| FY2010 | Dec 31, 2010 | -$76.01M | – |
| FY2009 | Dec 31, 2009 | -$58.81M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.67M | -14.3% |
| Q2 FY2026 | Jun 30, 2026 | $51.54M | +16.9% |
| Q1 FY2026 | Mar 31, 2026 | $34.79M | -28.4% |
| Q4 FY2025 | Dec 31, 2025 | $54.50M | -8.0% |
| Q3 FY2025 | Sep 30, 2025 | $48.61M | +0.4% |
| Q2 FY2025 | Jun 30, 2025 | $44.07M | +0.8% |
| Q1 FY2025 | Mar 31, 2025 | $48.62M | +31.2% |
| Q4 FY2024 | Dec 31, 2024 | $59.24M | +78.9% |
| Q3 FY2024 | Sep 30, 2024 | $48.42M | +10.8% |
| Q2 FY2024 | Jun 30, 2024 | $43.72M | +14.5% |
| Q1 FY2024 | Mar 31, 2024 | $37.05M | +44.4% |
| Q4 FY2023 | Dec 31, 2023 | $33.11M | +273.4% |
| Q3 FY2023 | Sep 30, 2023 | $43.72M | +178.8% |
| Q2 FY2023 | Jun 30, 2023 | $38.18M | -51.7% |
| Q1 FY2023 | Mar 31, 2023 | $25.65M | -73.9% |
| Q4 FY2022 | Dec 31, 2022 | $8.87M | -91.0% |
| Q3 FY2022 | Sep 30, 2022 | $15.68M | -83.8% |
| Q2 FY2022 | Jun 30, 2022 | $79.02M | -6.6% |
| Q1 FY2022 | Mar 31, 2022 | $98.09M | +16.6% |
| Q4 FY2021 | Dec 31, 2021 | $98.38M | +15.4% |
| Q3 FY2021 | Sep 30, 2021 | $96.71M | +29.7% |
| Q2 FY2021 | Jun 30, 2021 | $84.61M | +6.0% |
| Q1 FY2021 | Mar 31, 2021 | $84.11M | +14.5% |
| Q4 FY2020 | Dec 31, 2020 | $85.28M | +27.5% |
| Q3 FY2020 | Sep 30, 2020 | $74.56M | +29.9% |
| Q2 FY2020 | Jun 30, 2020 | $79.79M | +41.2% |
| Q1 FY2020 | Mar 31, 2020 | $73.47M | -4.2% |
| Q4 FY2019 | Dec 31, 2019 | $66.89M | +39.8% |
| Q3 FY2019 | Sep 30, 2019 | $57.40M | +32.0% |
| Q2 FY2019 | Jun 30, 2019 | $56.50M | +168.3% |
| Q1 FY2019 | Mar 31, 2019 | $76.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $47.86M | – |
| Q3 FY2017 | Sep 30, 2017 | $43.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.06M | – |
See a number that looks wrong?